Arrhythmias & electrophysiology

Diagnosis to Ablation in Persistent Atrial Fibrillation (AF): Any Time Can Be a Good Time to Ablate

JACC Clin ElectrophysiolPublished Secondary analysis of the CAPLA randomised trial

Primary result · AF recurrenceResult — go to the resultHazard ratio 1.607 95% CI 1.005–2.570

Authors' conclusion

In a cohort of patients with persistent AF undergoing ablation in a prospective trial with standardized entry criteria and intensive electrocardiogram monitoring, those with shorter DAT had lower rates of AF recurrence. However, differences were modest, and all quartiles demonstrated very low AF burden and improvements in quality of life.

Study context

Population
Patients with persistent AF undergoing catheter ablation (PVI ± posterior wall isolation) in the CAPLA trialmedian diagnosis-to-ablation time (DAT) 28 months
Participants
334 patients
Comparison
DAT quartiles
  • Q1n = 84reference
  • Q2n = 85
  • Q3n = 84
  • Q4n = 81
Primary endpoint
AF recurrence (after 3-month blanking period)
Follow-up
12 months
Methodological detailsmulticentre
  • Multicentre

Primary result

AF recurrence

Hazard ratio

1.607

95% CI 1.005–2.570

P = 0.048

By group

Q4vs Q1
HR 1.607 (95% CI 1.005–2.570); P = 0.048

As reported in the abstract

Further findings

OutcomeQ1Q2Q3Q4P value
AF burdenQ4 vs Q1 · median0% (IQR 0%–0.47%)— not stated in the abstract— not stated in the abstract0.33% (IQR 0%–4.6%)P = 0.002
Quality of life change (AFEQT)Δ28.8 ± 24Δ24.4 ± 23.4Δ21.7 ± 26.6Δ24.6 ± 21.4

— not stated in the abstract

Quality of life change (AFEQT) — Improved markedly in all quartiles
P = 0.331

Original publication

Diagnosis to Ablation in Persistent AF: Any Time Can Be a Good Time to Ablate. JACC Clin Electrophysiol. Published July 2024. doi:10.1016/j.jacep.2024.05.031

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.